Introduction
============

Osteoarthritis (OA), the most common form of arthritis, is a chronic disease characterized by the slow degradation of cartilage, pain, and increasing disability. The disease can have an impact on several aspects of a patient\'s life, including functional and social activities, relationships, socioeconomic status, body image, and emotional well-being \[[@B1]\]. Currently available pharmacological therapies target palliation of pain and include analgesics (i.e. acetaminophen, cyclooxygenase-2-specific inhibitors, nonselective nonsteroidal anti-inflammatory drugs, tramadol, opioids), intra-articular therapies (glucocorticoids and hyaluronan \[hyaluronic acid\] \[HA\]), and topical treatments (i.e. capsaicin, methylsalicylate) \[[@B2]\].

Intra-articular treatment with HA and hylans (see Table [1](#T1){ref-type="table"} for definitions) has recently become more widely accepted in the armamentarium of therapies for OA pain \[[@B2]\]. HA is responsible for the viscoelastic properties of synovial fluid. This fluid contains a lower concentration and molecular weight (MW) of HA in osteoarthritic joints than in healthy ones \[[@B3]\]. Thus, the goal of intra-articular therapy with HA is to help replace synovial fluid that has lost its viscoelastic properties. The efficacy and tolerability of intra-articular HA for the treatment of pain associated with OA of the knee have been demonstrated in several clinical trials \[[@B4]-[@B14]\]. Three (hylan G-F 20) to five (sodium hyaluronate) injections can provide relief of knee pain from OA for up to 6 months \[[@B6],[@B7],[@B11]\]. Intra-articular hylan or HA is also generally well tolerated, with a low incidence of local adverse events (from 0% to 13% of patients) \[[@B5],[@B6],[@B8],[@B11],[@B12]\] that was similar to that found with placebo \[[@B6],[@B11]\].

Because the residence time of exogenously administered HA in the joint is relatively short, HA probably has physiological effects in the joint that contribute to its effects in the joint over longer periods. The exact mechanism(s) by which intra-articular HA or hylans relieve pain is currently unknown. Improvements in OA with administration of HA have been shown in both electrophysiology and animal pain model studies \[[@B15]-[@B17]\]; Gomis A, Pawlak M, Schmidt RF, Belmonte C: **Effects of elastoviscous substances on the mechanosensitivity of articular pain receptors**. Presented at the Osteoarthritis Research Society International World Congress on Osteoarthritis, September 2001, Washington, DC, USA\]. HA treatment has also been shown to have protective effects on cartilage in experimental models of OA \[[@B18]-[@B20]\]. *In vitro*studies also show that HA has beneficial effects on the extracellular matrix, immune cells, and inflammatory mediators \[[@B21]-[@B26]\]. This article provides a brief introduction to the pathophysiology of OA and reviews the current scientific literature regarding the physiological effects of HA and hylans, focusing on antinociceptive effects, possible protective effects on cartilage, and effects on molecular and cellular factors involved in OA disease progression. The effects of HA and hylans on these factors may provide insight into the mechanism by which HA and hylans elicit their clinical benefits.

Methods
=======

Relevant literature was identified by searching MEDLINE from 1966 through July 2002. The following search words were used alone and in combination when appropriate: hyaluronan, hyaluronic acid, sodium hyaluronate, hylan, OA, knee, cartilage, synovium, pathophysiology, extracellular matrix, proteoglycans (PGs), aggrecanase, inflammation, immunology, proteases, matrix metalloproteinases (MMPs), cytokines, proinflammatory mediators, nitric oxide (NO), prostaglandins, lymphocytes, nociceptors, and mechanoreceptors. Additional references were located by consulting the bibliographies of MEDLINE sources.

Pathophysiology of osteoarthritis
=================================

OA is characterized by a slow degradation of cartilage over several years. In normal cartilage, a delicate balance exists between matrix synthesis and degradation; in OA, however, cartilage degradation exceeds synthesis. The balance between synthesis and degradation is affected by age and is regulated by several factors produced by the synovium and chondrocytes, including cytokines, growth factors, aggrecanases, and MMPs \[[@B27]-[@B32]\] (Fig. [1](#F1){ref-type="fig"}).

In addition to water, the extracellular matrix is composed of PGs entrapped within a collagenous framework or fibrillary matrix (Fig. [2](#F2){ref-type="fig"}) \[[@B33]\]. PGs are made up of glycosaminoglycans attached to a backbone made of HA \[[@B33]\]. In OA, the collagen turnover rate increases, the PG content decreases, the PG composition changes, and the water content increases \[[@B33]\]. The size of HA molecules \[[@B3]\] and their concentration \[[@B34]\] in synovial fluid also decrease in OA. A significant PG in articular cartilage is aggrecan, which binds to HA and helps provide the compressibility and elasticity of cartilage \[[@B32]\]. Aggrecan is cleaved by aggrecanases, leading to its degradation and to subsequent erosion of cartilage \[[@B34],[@B35]\]. The loss of aggrecan from the cartilage matrix is one of the first pathophysiological changes observed in OA \[[@B32]\].

Cytokines produced by the synovium and chondrocytes, especially IL-1 and tumor necrosis factor alpha (TNF-α), are also key players in the degradation of cartilage \[[@B29]\]. IL-1β is spontaneously released from cartilage of OA but not normal cartilage \[[@B36]\]. Both IL-1β and TNF-α stimulate their own production and the production of other cytokines (e.g. IL-8, IL-6, and leukotriene inhibitory factor), proteases, and prostaglandin E~2~(PGE~2~) \[[@B30]\]. Synthesis of the inflammatory cytokines IL-1 and TNF-α and expression of their receptors are enhanced in OA \[[@B29]-[@B31]\]. Both cytokines have been shown to potently induce degradation of cartilage *in vitro*\[[@B31]\]. Other proinflammatory cytokines overexpressed in OA include IL-6, IL-8, IL-11, and IL-17, as well as leukotriene inhibitory factor \[[@B30]\]. The production of the chemokine RANTES (regulated upon activation, normal T-cell expressed and secreted), is also high in OA cartilage compared with normal cartilage, is stimulated by IL-1, and increases the release of PGs from cartilage \[[@B37]\].

Prostaglandins and leukotrienes may also be involved in cartilage destruction in OA. PGE~2~is spontaneously produced by OA cartilage \[[@B38]\] and leukotriene B4 is elevated in the synovial fluid of OA \[[@B36]\]. Although IL-1β stimulates the release of PGE~2~\[[@B39]\], the role of PGE in cartilage biology is unclear, since studies show both anabolic and catabolic effects of PGE on cartilage \[[@B38]\].

The extracellular matrix in cartilage is degraded by locally produced MMPs. Elevated levels of stromelysin (MMP-3), collagenases (MMP-1, -8, and -13), and gelatinases (MMP-2 and -9) have also been found in chondrocytes or the articular cartilage surface in OA \[[@B29],[@B31]\]. The activity of many MMPs increases in OA by either an increase in their own synthesis, an increased activation by their proenzymes, or decreased activity of their inhibitors \[[@B29]\]. Proinflammatory cytokines, including IL-1, TNF-α, IL-17, and IL-18, increase synthesis of MMPs, decrease MMP enzyme inhibitors, and decrease extracellular matrix synthesis \[[@B29]\]. To further exacerbate the degradative activity in OA, expression levels of tissue inhibitor of metalloproteinases (TIMP)-1 are reduced \[[@B29]\].

In an attempt to reverse the breakdown of the extracellular matrix, the chondrocytes increase synthesis of matrix components including PGs \[[@B29]\]. Even though this activity increases, a net loss of PG in the upper cartilage layer is seen, because the increased activity has been observed only in the middle and deeper layers of cartilage \[[@B29]\]. Elevated anti-inflammatory cytokines found in the synovial fluid of OA include IL-4, IL-10, and IL-13 \[[@B30]\]. Their role is to reduce production of IL-1, TNF-α, and MMPs, increase TIMP-1, and inhibit prostaglandin release \[[@B32],[@B40]\]. Local production of growth and differentiation factors such as insulin-like growth factor 1, transforming growth factors, fibroblastic growth factors, and bone morphogenetic proteins also stimulate matrix synthesis \[[@B29],[@B41]\].

The production of NO, another inflammatory mediator synthesized by the cartilage in OA and well documented in experimental OA, is stimulated by the proinflammatory cytokines IL-1 and TNF-α \[[@B29]-[@B31],[@B36]\]. NO may be involved in cartilage catabolism by inhibiting the synthesis of collagen and PG, enhancing MMP activity, reducing the synthesis of an IL-1 receptor antagonist by chondrocytes, and increasing susceptibility to cell injury (i.e. apoptosis) \[[@B30],[@B36],[@B42]\]. NO can also inhibit the attachment of fibronectin to chondrocytes, thus enhancing PG synthesis \[[@B42]\].

Additionally, NO can induce apoptosis of chondrocytes in OA \[[@B30]\]. Chondrocyte apoptosis occurs in both human and experimental OA and is correlated with the severity of cartilage destruction \[[@B42]\]. Apoptosis of chondrocytes in OA has been shown to have a higher incidence in OA than in normal cartilage, to be present close to the articular surface, and to be significantly correlated with OA grade \[[@B43],[@B44]\]. Death of chondrocytes could easily lead to reduced matrix production, since chondrocytes are the only source of matrix components and their population is not renewed \[[@B29]\]. Depletion of PGs was observed in cartilage areas that contained apoptotic chondrocytes \[[@B43]\]. Cellular products of apoptosis may also contribute to the pathophysiology of OA, because apoptotic cells are not effectively removed from cartilage \[[@B29]\] due to its avascular nature and can cause pathogenetic events such as abnormal cartilage calcification or extracellular matrix degradation \[[@B43]\].

Role of hyaluronan in the synovial fluid
========================================

HA is responsible for the viscoelastic quality of synovial fluid that acts as both a lubricant and shock absorber \[[@B3]\]. In synovial fluid, HA coats the surface of the articular cartilage and shares space deeper in the cartilage among collagen fibrils and sulfated PGs \[[@B3]\]. In this respect, HA probably protects the cartilage and blocks the loss of PGs from the cartilage matrix into the synovial space, maintaining the normal cartilage matrix \[[@B3]\]. Similarly, HA may also help prevent invasion of inflammatory cells into the joint space.

In acute and chronic inflammatory processes of the joint, the size of HA molecules decreases at the same time as the number of cells in the joint space increases \[[@B3]\]. In synovial fluid from knee joints in OA, concentrations of HA, glycosaminoglycans, and keratan sulfate are lower than in synovial fluid from normal knee joints \[[@B34]\]. Additionally, experiments using rabbit synovial cells showed that the proinflammatory cytokines IL-1 and TNF-α stimulate the expression of HA synthetase \[[@B45]\], which may contribute to the fragmentation of HA under inflammatory conditions.

Exogenous HA may facilitate the production of newly synthesized HA. When synovial fibroblasts from OA knees were cultured with HA formulations of various MWs (3.4 × 10^5^to 4.7 × 10^6^), the amount of newly synthesized HA in response to the exogenous HA was both concentration- and MW-dependent \[[@B21]\]. Higher-MW agents stimulated the synthesis of HA more than lower-MW formulations and an optimal concentration was noted for each MW \[[@B21]\].

HA in the synovial fluid binds to chondrocytes via the CD44 receptor \[[@B46],[@B47]\], supporting a role for HA in healthy cartilage. The primary means of retention and anchoring of PG aggregates to chondrocytes is the CD44 HA receptor \[[@B48]\]. When expression of CD44 was suppressed in bovine articular cartilage slices, a near-complete loss of PG staining was observed \[[@B48]\]. A similar decrease in PG staining was found when very small HA molecules were used to block the binding of HA to the CD44 receptor \[[@B47]\]. CD44 adhesion to HA has also been shown to mediate chondrocyte proliferation and function \[[@B49]\].

Hyaluronan and nociception
==========================

Relief of knee pain from OA with HA in clinical studies may be due to the effects of HA on nerve impulses and nerve sensitivity. Inflammation of the knee joint influences excitability of nociceptors of articular nerves \[[@B15]\]. In experimental OA, these nerves become hyperalgesic, spontaneously discharge, and are sensitive to non-noxious joint movements \[[@B15]\]. Administration of HA to isolated medial articular nerves from an experimental model of OA significantly decreased ongoing nerve activity as well as movement-evoked nerve activity \[[@B15]\]. In another model, nerve impulses evoked by movement of an inflamed knee were significantly reduced with hylan G-F 20 to about 60% of that of the controls (Gomis A, Pawlak M, Schmidt RF, Belmonte C: **Effects of elastoviscous substances on the mechanosensitivity of articular pain receptors.**Presented at the Osteoarthritis Research Society International World Congress on Osteoarthritis, September 2001, Washington, DC, USA). These authors reported that HAs with lower MWs had either less of an effect or no effect on nerve impulse frequency. Impulse discharge and firing frequency of activated nerve sensory fibers decreased to 65% and 45% of that of control values, respectively, when hylan was administered \[[@B50]\]. Mechanical forces on stretch-activated ion channels are involved in depolarization of the articular nerve terminal. In the presence of hylan, these ion channels also have decreased mechanical sensitivity (de la Peña E, Pecson B, Schmidt RF, Belmonte C: **Effects of hylans on the response characteristics of mechanosensitive ion channels.**Presented at the 9th World Congress on Pain, Vienna, Austria 1999).

In a rat model, HA improved the abnormal gait of rats with experimentally induced OA in a dose-dependent manner, indicating an antinociceptive effect of HA \[[@B16]\]. This effect may be mediated through the attenuation of prostaglandin E~2~(PGE~2~) and bradykinin synthesis, since HA inhibited their synthesis in a MW-dependent manner \[[@B16]\]. Further, HA has been shown to induce analgesia in a bradykinin-induced model of joint pain in rats \[[@B17]\]. This analgesic action was also MW-dependent, as significant effects were observed at lower concentrations with a higher-MW formulation than with lower-MW HAs \[[@B17]\].

Lastly, HA may have direct or indirect effects on substance P, which can be involved in pain \[[@B51]\]. Since substance P interacts with excitatory amino acids, prostaglandins, and NO, the effects of HA on these factors can indirectly affect the pharmacology of substance P \[[@B51]\]. Additionally, HA has been shown to inhibit an increased vascular permeability induced by substance P \[[@B51]\].

Molecular and cellular effects of hyaluronan
============================================

Many effects of exogenous HA on the extracellular matrix, inflammatory mediators, and immune cells have been reported in *in vitro*studies. The influence of HA on these factors may contribute to cartilage protection in OA.

Effects of hyaluronan on the extracellular matrix
-------------------------------------------------

*In vitro*experiments indicate that HA administration can enhance the synthesis of extracellular matrix proteins, including chondroitin and keratin sulfate, and PGs (Table [2](#T2){ref-type="table"}). In rabbit chondrocytes cultured on collagen gels, HA increased the synthesis of the glycosaminoglycan chondroitin sulfate \[[@B52]\]. Release of keratan sulfate, a PG fragment, into synovial fluid is also suppressed by HA in an ovine model \[[@B53]\]. In a clinical study with HA in which patients served as their own controls, keratin sulfate was lower in more knees treated with HA (10/12) than in knees treated with saline (4/12) \[[@B54]\].

Beneficial effects on PG synthesis have also been demonstrated *in vitro*with HA. This glycosaminoglycan has been shown to increase PG synthesis in equine articular cartilage \[[@B22]\], rabbit chondrocytes \[[@B55]\], and bovine articular cartilage treated with IL-1, which has been shown to reduce PG synthesis *in vitro*\[[@B56]\]. An increase in high-MW PG production was also demonstrated with HA in cells of rabbit ligament \[[@B57]\]. In another study, although HA alone decreased PG production from chondrocytes of patients with knee OA, HA countered the reduction of PG production induced by IL-1α \[[@B58]\]. HA has also been shown to suppress the release of PGs from rabbit chondrocytes \[[@B19],[@B59]\] and bovine articular cartilage \[[@B60]\] in the absence and in the presence of IL-1. Additionally, resorption of PGs from cartilage explants was inhibited with hylan; in these experiments, high-viscosity hylan was more effective than a low-viscosity form \[[@B61]\]. A reduction in collagen gene expression induced by IL-1β in rabbit articular chondrocytes has also been suppressed by HA \[[@B62]\]. In an *in vivo*model of canine OA, a reduced amount of glycosaminoglycan release was found in hyaluronate-treated joints compared with an increased release in untreated joints \[[@B63]\].

HA has also been shown to suppress cartilage damage by fibronectin fragments *in vitro*and *in vivo*. Fragments of fibronectin bind and penetrate cartilage and subsequently increase levels of MMPs and suppress PG synthesis \[[@B64]\]. In explant cultures of human cartilage, HA blocked PG depletion induced by fibronectin fragments \[[@B65]\]. This protective effect was associated with its coating of the articular surface, suppression of fibronectin-fragment-enhanced stromelysin-1 release, increased PG synthesis, and restoration of PGs in damaged cartilage \[[@B65]\]. Similar effects of HA on PGs were observed in bovine articular cartilage *in vitro:*HA suppressed fibronectin-fragment-mediated PG depletion and partially restored PGs in the damaged cartilage \[[@B64]\]. HA also attenuated the enhanced stromelysin-1 release induced with fragments of fibronectin \[[@B64]\]. When fibronectin fragments were intra-articularly administered into rabbit knees, the decrease in PG content was reduced with HA \[[@B66]\].

Effects of hyaluronan on inflammatory mediators
-----------------------------------------------

HA has significant effects on inflammatory mediators, including cytokines, proteases and their inhibitors, and prostaglandins (Table [3](#T3){ref-type="table"}), that may translate into cartilage protection. *In vitro*studies show that HA alters the profile of inflammatory mediators such that the balance between cell matrix synthesis and degradation is shifted away from degradation. The proinflammatory cytokine TNF-α and its receptor were not evident in canine atrophied articular cartilage treated with HA by immunostaining but were observed in untreated cartilage \[[@B67]\]. In the synovium of rabbits in the early development of OA, HA also reduced the expression of IL-1β and stromelysin (MMP-3) \[[@B23]\], two mediators known to play a role in cartilage degradation. In bovine articular chondrocytes, high-MW HA stimulated the production of TIMP-1, the MMP inhibitor \[[@B68]\]. Although HA also stimulated stromelysin activity in the same study, the increase was inconsistent and was less with a high-MW than with a low-MW HA \[[@B68]\]. Further, the stromelysin/TIMP-1 ratio was reduced with the high-MW HA, suggesting a cartilage protective effect \[[@B68]\]. The plasminogen activator system, shown to be active in synovial fibroblasts of rheumatoid arthritis (RA), is also influenced by HA \[[@B24]\]. In synovial fibroblasts from OA and RA patients, HA reduced the secreted antigen and activity of urokinase plasminogen activator, as well as its receptor \[[@B24]\]. Similarly, intra-articular administration of HA decreased urokinase plasminogen activator activity in the synovial fluid of patients who showed clinical improvement \[[@B69]\].

Metabolites of arachidonic acid such as various prostaglandins mediate, in part, inflammatory responses. HA reduced arachidonic acid release \[[@B70]\] and IL-1α-induced PGE~2~production \[[@B71]\] in a dose- and MW-dependent manner; the higher the MW and concentration, the more potent the inhibition. Intra-articular injection of HA in the temporomandibular joint reduced levels of prostaglandin F~2α~, 6-keto-prostaglandin F~1α~, and leukotriene C~4~\[[@B72]\]. In synovial fluid from the knees of patients with OA and RA, intra-articular HA reduced the levels of PGE~2~\[[@B73],[@B74]\] and stimulated cAMP concentrations, another mechanism by which HA may act in an anti-inflammatory manner \[[@B74]\].

HA also has antioxidant effects in various systems. Most recently, in an *in vitro*assay it showed such effects that were both MW- and dose-dependent \[[@B75]\]. Using two different antioxidant models, Sato and colleagues found that both HA and one of its components, D-glucuronic acid, reduced the amount of reactive oxygen species \[[@B76]\]. Interleukin-1-induced oxidative stress \[[@B77]\] and superoxide anion \[[@B78]\] in bovine chondrocytes were also reduced with HA in a dose-dependent manner. High-MW HA also protects against the damage to articular chondrocytes by oxygen-derived free radicals, which are known to play a role in the pathogenesis of arthritic disorders \[[@B79]\]. Lastly, in avian embryonic fibroblasts, HA reduced cell damage induced by hydroxyl radicals in a MW- and dose-dependent manner \[[@B80]\].

The effects of HA on NO, well recognized for its role in inflammation, may be tissue specific. Production of NO from the meniscus and synovium of a rabbit OA model was significantly reduced with HA treatment \[[@B81]\]. Other experiments showed that HA did not affect NO production from articular cartilage \[[@B82],[@B83]\]. In hepatic cells, fragments of HA increased the expression of the inducible form of NO synthase, while high-MW HA did not have an effect on its expression \[[@B84]\]. In the synovial fluid of OA, it could be speculated that the presence of HA fragments or low-MW HA may induce the inducible form of NO synthase, consequently increasing NO concentration in the disease state. Introducing a high-MW HA could prevent the production of NO in OA; however, further studies are needed to support this hypothesis.

Effects of hyaluronan on immune cells
-------------------------------------

Besides altering the production and activity of inflammatory mediators and proteases, HA can change the behavior of immune cells. Its effects on immune cells are summarized in Table [4](#T4){ref-type="table"}. HA has been shown to reduce the motility of lymphocytes; this observation occurred with physiological fluids (i.e. synovial fluid and liquid vitreous) containing a high concentration of HA \[[@B25]\]. When the HA in these fluids was digested with hyaluronidase, it no longer inhibited the motility, indicating that the motility inhibition depended on the molecular size and polysaccharide conformation of the molecule \[[@B25]\]. Inhibition of lymphocyte proliferation by HA has also been shown to be dependent on the MW as well as the concentration of HA \[[@B85]\]. Similarly, lymphocyte stimulation *in vitro*was shown to be suppressed by HA in a MW-dependent manner \[[@B86]\].

Leukocyte function, including phagocytosis, adherence, and mitogen-activated stimulation, can be modulated by HA. Both human and equine synovial fluids have been shown to inhibit macrophage phagocytosis, an effect that was dependent on the viscosity of the fluid \[[@B26]\]. Similarly, high-MW HA inhibited macrophage phagocytosis in a dose-dependent manner, while a low-MW hyaluronate did not inhibit phagocytosis \[[@B87]\]. Neutrophil phagocytosis was also significantly inhibited by HA at a concentration of 4 mg/ml (close to that of normal synovial fluid) but not at 1 mg/ml \[[@B88]\].

The function of the polymorphonuclear (PMN) leukocyte is also influenced by HA. All concentrations of HA tested reduced PMN leukocyte migration in a dose-dependent manner \[[@B89]\]. HA also inhibited PMN leukocyte migration induced by leukotriene B4, a potent chemotactic factor \[[@B89]\]. Additionally, activation of PMN leukocytes, as measured by superoxide generation, was inhibited with hylan concentrations greater than 0.5 mg/ml \[[@B61]\]. The degree of this inhibition was directly correlated with the viscosity of the hylan sample \[[@B61]\]. Finally, HA has been shown to increase the negative charge and number of hydrophobic sites on the cell surface of PMN leukocytes \[[@B90]\], which may alter cell--cell communication in a way that has yet to be determined. In contrast, HA has been shown to stimulate PMN leukocyte function both *in vitro*and *in vivo*\[[@B91]\]. These conflicting results may be due to the fact that in the latter study the leukocytes were isolated from patients with impaired host resistance.

Cartilage degradation associated with neutrophils has been associated with neutrophil adhesion to cartilage *in vitro*\[[@B92]\]. HA was shown to inhibit this neutrophil-induced cartilage degradation in a dose- and MW-dependent fashion \[[@B92]\]. Neutrophil aggregation and adhesion were also inhibited by HA in a dose- and MW-dependent manner, but this inhibition was not dependent on HA viscosity \[[@B93]\].

Cartilage effects of hyaluronan and hylans
==========================================

The effects of HA and hylans on cartilage histology are well documented in experimental animal studies, but strong clinical trial data is lacking (Table [5](#T5){ref-type="table"}).

Experimental OA studies
-----------------------

Histological data demonstrate a protective effect of HA on cartilage in various animal models of experimental OA. Overall, the therapeutic use of HA has been shown to reduce the severity of OA and to maintain cartilage thickness, area, and surface smoothness. In rabbits with cartilage degeneration from immobilization, HA reduced the area of cartilage ulceration observed and prevented loss of chondrocytes \[[@B94]\]. Several beneficial effects of HA on cartilage have also been demonstrated in experimental OA induced by anterior cruciate ligament transection in rabbits. In general, the grade of cartilage damage 9 weeks after treatment was less severe in animals treated with HA than in animals given the vehicle only or not treated \[[@B19]\]. When compared with the cartilage of nonsurgical contralateral controls, the cartilage of HA-treated joints was equal in thickness and area, while cartilage thickness and area in vehicle-treated and untreated joints were significantly less than in controls \[[@B19]\]. Additionally, surface roughness was significantly less in HA-treated animals than in vehicle-treated and untreated animals \[[@B19]\]. A 21-week study found similar protective effects on cartilage \[[@B95]\]. Even after 6 months, HA has been shown to enhance meniscal regeneration and inhibit cartilage degradation in rabbits with partial meniscectomy \[[@B96]\]. The grade of OA tended to be less severe in animals given HA than in those give the vehicle only, and more intense immunostaining for glycosaminoglycans was observed with HA treatment compared with the vehicle \[[@B96]\].

Other studies investigating the effects of HA on meniscus injury and repair in rabbits found no differences attributable to treatment. However, this may have been due to the timing of HA treatment \[[@B97],[@B98]\]. In these studies, HA was administered 1 week after surgery \[[@B97],[@B98]\], as opposed to 4 weeks after surgery in the other studies just mentioned \[[@B19],[@B95]\]. Similarly, in other studies using a canine OA model, hylan reduced disease severity when animals were treated 2 months after surgery \[[@B99]\]; however, the effects on cartilage when hylan or HA was injected immediately after surgery were similar to those of the vehicle \[[@B99],[@B100]\]. When HA was given 3, 6, or 12 weeks after anterior cruciate ligament resection in dogs (Pond-Nuki OA model), the cartilage was smooth and did not display deep fissures or cracks as in the placebo-treated animals \[[@B101]\]. Another study using the Pond-Nuki model showed that HA treatment significantly reduced OA progression as measured by a reduced OA grade in comparison with controls \[[@B20]\].

The extent of beneficial effect on cartilage observed with HA may largely depend on the MW of the HA formulation. In a study of OA in rabbits, cartilage degeneration was less in all HA groups tested, but was significantly less with HA with a MW of 2.02 × 10^6^ than HA with a MW of 9.5 × 10^5^\[[@B102]\]. Similarly, the histology of articular cartilage and synovial tissue was significantly better with an HA of MW = 2.02 × 10^6^than with an HA of MW = 9.8 × 10^5^\[[@B103]\]. Shimizu and colleagues found that the protective effects of hylan G-F 20 (80% hylan A \[MW = 6.0 × 10^6^\], 20% hylan B gel) and an HA of MW 8 × 10^5^on articular cartilage were similar to each other, but better than those observed with HAs of MW 5--7 × 10^5^or 3.6 × 10^6^\[[@B18]\].

Clinical trials
---------------

Until now, the effects of HA on cartilage have not been demonstrated in any randomized, placebo-controlled trials. Results from trials of other types of study design presented here warrant further study in more rigorous trials. In an open-label study (*n*= 40) of five weekly injections of HA, both the cartilage and the synovial membrane were improved when measured 6 months after the injection \[[@B104]\]. In the nine patients with grade II OA who were assessed, the thickness of the superficial amorphous cartilage layer improved significantly between the baseline and final evaluations \[[@B104]\]. A significant reduction in the thickness of the synovial membrane and in the number of infiltrating mononuclear cells indicated reduced inflammation of the synovium \[[@B104]\]. In a study where patients were randomized to conventional therapy and then arthroscopically evaluated for severity of chondropathy, cartilage deterioration was observed in both control and HA groups, but was significantly less in the HA group as measured by an investigator overall visual analog score and the Société Française d\'Arthroscopie (SFA) scoring system \[[@B10]\]. Although these initial clinical trials have several limitations, including an open-label design, unblinded evaluation, lack of appropriate controls, and small sample size, the data from these studies warrant further study of the effects of HA on cartilage protection and disease progression in more rigorous, prospective, randomized, controlled, double-blind clinical studies.

The effects of sodium hyaluronate or methylprednisolone acetate on articular cartilage and the synovium have also been compared in a clinical setting \[[@B105],[@B106]\]. In the synovium of HA-treated knees, the number and aggregation of synoviocytes decreased, and both treatments reduced the number of inflammatory cells, including macrophages, lymphocytes, and mast cells \[[@B105]\]. Sodium hyaluronate (five weekly injections) also significantly improved the compactness and thickness of the amorphous superficial cartilage layer 6 months after treatment, in comparison with baseline \[[@B106]\]. Cartilage changes with methylprednisolone acetate 6 months after treatment were not significantly different from baseline, and the thickness of the superficial amorphous layer was significantly improved with HA compared with intra-articular steroid \[[@B106]\]. Chondrocyte density was also significantly higher with HA compared with baseline and steroid treatment \[[@B106]\]. Lastly, many of the morphometric parameters of the chondrocytes were significantly better with HA than with methylprednisolone \[[@B106]\]. Because the migration and proliferation of chondrogenic precursor cells to the site of cartilage injury are necessary for cartilage repair, an *in vitro*study examined the effects of HA and basic fibroblastic growth factor on the migration of rabbit synovial cell and chondrocyte migration \[[@B107]\]. The rate of synovial cell migration was enhanced with HA alone, and HA increased chondrocyte migration in the presence of this growth factor \[[@B107]\].

Conclusions
===========

The clinical effects of HA on pain associated with OA of the knee are probably mediated by several factors. *In vitro*and *in vivo*studies indicate that HA can enhance PG synthesis and prevent its release from the cell matrix. Regarding inflammation, HA suppresses the production and activity of proinflammatory mediators and proteases as well as altering the function of certain immune cells. Histological evidence shows that HA prevents the degradation of cartilage and may promote its regeneration. Collectively, the physiological effects of intra-articular HA reviewed here support a multifactorial mechanism for HA and hylans in the treatment of pain from knee OA. Future studies investigating the effects of HA and hylans on cartilage in well-controlled clinical studies may help determine whether intra-articular HA and hylans aid in chondroprotection and slowing the progression of disease, and whether the MW of the HA formulation contributes to its efficacy.
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![Several factors contribute to the breakdown and synthesis of cartilage. In osteoarthritis (OA), the balance between cartilage degradation and synthesis leans toward degradation. BMP, bone morphogenetic protein; bFGF, basic fibroblastic growth factor; IGF, insulin-like growth factor; IL, interleukin; MMP, matrix metalloproteinase; PG, proteoglycan; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinases; TNF, tumor necrosis factor.](ar623-1){#F1}

![The extracellular matrix of cartilage is composed of proteoglycans attached to a backbone of hyaluronic acid that is intertwined among collagen fibrils. Proteoglycans have both chondroitin-sulfate- and keratin-sulfate-rich regions, and link proteins facilitate binding of aggrecan to hyaluronic acid.](ar623-2){#F2}

###### 

Definition and characteristics of hyaluronan (hyaluronic acid) and hylans

  Definition                                           Characteristics
  ---------------------------------------------------- --------------------------------------------------------------------------------------------
  Hyaluronan (hyaluronic acid) or sodium hyaluronate   Long, nonsulfated, straight chains of variable length
                                                       Repeating disaccharide unit of *N*-acetylglucosamine and glucuronic acid
                                                       Forms a randomized coil in physiological solvents
                                                       Average MW 4--5 million Da
  Hylans                                               Crosslinked hyaluronan chains in which the carboxylic and *N*-acetyl groups are unaffected
                                                       MW of Hylan A is 6 million Da
                                                       Can be water-insoluble as a gel (e.g. hylan B) or membrane bound

MW, molecular weight.

###### 

Effects of hyaluronan (hyaluronic acid) and hylans on the extracellular matrix

  Effect                                                 Reference                              Experimental model; treatment                                                                                                                                   MW-dependent   Dose-dependent
  ------------------------------------------------------ -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ----------------
  Enhanced HA synthesis                                  Smith & Ghosh, 1987 \[[@B21]\]         Synovial fibroblasts of patients with normal joints and with OA; HA of various MWs and concentrations                                                           Yes            Yes
  Increased synthesis of chondroitin sulfate             Kawasaki *et al.*, 1999 \[[@B52]\]     Rabbit chondrocytes; various HA doses                                                                                                                           N/A            Yes
  Enhanced PG synthesis                                  Frean *et al.*, 1999 \[[@B22]\]        Equine articular cartilage; various HA doses                                                                                                                    N/A            Yes
                                                         Fukuda *et al.*, 1996 \[[@B56]\]       Bovine articular cartilage; various HA doses                                                                                                                    N/A            Yes
  Enhanced PG synthesis in the presence of IL-1α         Stöve *et al.*, 2002 \[[@B58]\]        Human chondrocytes from OA knee patients; HA, IL-1α or HA + IL-1α                                                                                               N/A            N/A
  Increased production of high-MW PGs                    Kikuchi *et al.*, 1996 \[[@B57]\]      Rabbit ligamental cells; various HA doses                                                                                                                       N/A            Yes
  Increased content and influenced distribution of PGs   Kikuchi *et al.*, 2001 \[[@B108]\]     Rabbit chondrocytes; various HA concentrations                                                                                                                  N/A            Yes
  Suppressed PG release from cartilage                   Yoshioka *et al.*, 1997 \[[@B19]\]     Rabbit ACL transection; HA (five weekly injections) given 4 weeks PS                                                                                            N/A            N/A
                                                         Larsen *et al.*, 1992 \[[@B61]\]       Bovine cartilage explants; HA or hylan                                                                                                                          N/A            N/A
  Suppressed PG release from cell matrix layer           Shimazu *et al.*, 1993 \[[@B59]\]      Rabbit chondrocytes; various MWs and doses of HA                                                                                                                No             Yes
  Decreased PG release from cartilage matrix             Morris *et al.*, 1992 \[[@B60]\]       Bovine articular cartilage; various doses of HA with or without IL-1β                                                                                           N/A            Yes
  Prevented PG breakdown from cartilage                  Ghosh *et al.*, 1995 \[[@B53]\]        Ovine meniscectomy; HA (five weekly injections) given 16 weeks PS; keratan sulfate peptide measured in SF 1 week preinjection and 1 and 4 weeks postinjection   N/A            N/A
  Protected extracellular matrix from degradation        Abatangelo *et al.*, 1989 \[[@B63]\]   Canine ACL resection (Pond-Nuki); HA given 7 days PS weekly for 6 weeks                                                                                         N/A            N/A

ACL, anterior cruciate ligament; HA, hyaluronan (hyaluronic acid); IL, interleukin; MW, molecular weight; OA, osteoarthritis; PG, proteoglycan; PS, postsurgery; SF, synovial fluid.

###### 

Effects of hyaluronan (hyaluronic acid) and hylans on inflammatory mediators

  Effect                                                                                      Reference                             Experimental model; treatment                                                                                                     MW-dependent   Dose-dependent
  ------------------------------------------------------------------------------------------- ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- -------------- ----------------
  Reduced levels of prostaglandins and leukotriene                                            Hirota *et al.*, 1998 \[[@B72]\]      Human synovial fluid of temporomandibular joint before and after injection of HA (2 injections 2 weeks apart)                     N/A            N/A
  Decreased levels of PGE~2~                                                                  Goto *et al.*, 2001 \[[@B73]\]        Synovial fluid of RA patients collected after five weekly HA injections                                                           N/A            N/A
  Lowered IL-1-induced PGE~2~production                                                       Yasui *et al.*, 1992 \[[@B71]\]       Human synovial cells from an OA patient; various MWs and doses of HA                                                              Yes            Yes
  Stimulated cAMP production; decreased levels of PGE~2~                                      Punzi *et al.*, 1989 \[[@B74]\]       Synovial fluid of patients with knee-joint effusion before and after injection of HA                                              N/A            N/A
  Reduced expression of IL-1 and stromelysin                                                  Takahashi *et al.*, 1999 \[[@B23]\]   Rabbit ACL transection; five weekly injections of HA 4 weeks PS; observations 9 weeks PS                                          N/A            N/A
  Suppressed production of TNF-α                                                              Comer *et al.*, 1996 \[[@B67]\]       Atrophied canine articular cartilage; HA with or without TGF-β every 4 days from day 56 to day 92                                 N/A            N/A
  Increased production of TIMP-1, the MMP inhibitor; reduced ratio of stromelysin to TIMP-1   Yasui *et al.*, 1992 \[[@B68]\]       Bovine articular chondrocytes; HA of various MWs                                                                                  Yes            N/A
  Decreased plasminogen activator activity and antigen                                        Nonaka *et al.*, 2000 \[[@B24]\]      Synovial fibroblasts of OA and RA patients; various doses of HA *in vitro*                                                        N/A            No
                                                                                              Nonaka *et al.*, 1999 \[[@B69]\]      Synovial fluid collected from OA patients before and after injection of HA                                                        N/A            N/A
  Reduced arachidonic acid release                                                            Tobetto *et al.*, 1992 \[[@B70]\]     Synovial cells of OA patients; various MWs and doses of HA                                                                        Yes            Yes
  Exhibited antioxidant effects                                                               Fukuda *et al.*, 2001 \[[@B77]\]      Bovine articular chondrocytes; various doses of HA                                                                                N/A            Yes
                                                                                              Fukuda *et al.*, 1997 \[[@B78]\]      Bovine chondrocytes; various doses of HA                                                                                          N/A            Yes
                                                                                              Moseley *et al.*, 2002 \[[@B75]\]     *In vitro*oxidation assay                                                                                                         Yes            Yes
  Protected cells from damage due to hydroxyl radicals                                        Presti & Scott, 1994 \[[@B80]\]       Chicken embryo fibroblasts; various MWs and doses of HAs                                                                          Yes            Yes
  Reduced NO production                                                                       Takahashi *et al.*, 2001 \[[@B81]\]   Rabbit ACL transection; five weekly HA injections 4 weeks PS; meniscus and synovial NO production assessed *in vitro*9 weeks PS                  

ACL, anterior cruciate ligament; HA, hyaluronan (hyaluronic acid); IL-1, interleukin-1; MMP, matrix metalloproteinase; MW, molecular weight; NO, nitric oxide; OA, osteoarthritis; PGE~2~, prostaglandin E~2~; PS, postsurgery; RA, rheumatoid arthritis; TGF-β, transforming growth factor beta; TIMP-1, tissue inhibitor of metalloproteinases-1; TNF-α, tumor necrosis factor alpha.

###### 

Effects of hyaluronan (hyaluronic acid) and hylans on immune cells

  Effect                                                                Reference                                 Experimental model; treatment                                      MW-dependent   Dose-dependent
  --------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------ -------------- ----------------
  Reduced lymphocyte motility                                           Balazs & Darzynkiewicz, 1973 \[[@B25]\]   Macrophages from various species; high- and low-MW HA              Yes            Yes
  Inhibited lymphocyte proliferation                                    Peluso *et al.*, 1990 \[[@B85]\]          Human mononuclear cells; high- and low-MW HA                       Yes            Yes
  Suppressed lymphocyte stimulation                                     Darzynkiewicz & Balazs, 1971 \[[@B86]\]   Human lymphocytes; various MWs and doses of HA                     Yes            Yes
  Inhibited macrophage phagocytosis and cell motility                   Balazs *et al.*, 1981 \[[@B26]\]          Mouse macrophages; human and equine synovial fluid                 N/A            N/A
                                                                        Forrester & Balazs, 1980 \[[@B87]\]       Mouse macrophages; high- and low-MW HAs                            Yes            Yes
  Inhibited phagocytosis and degranulation of neutrophils               Pisko *et al.*, 1983 \[[@B88]\]           Human neutrophils; various doses of HA                             N/A            Yes
  Reduced PMN leukocyte migration and activation                        Partsch *et al.*, 1989 \[[@B89]\]         PMN cells from OA patients; various HA doses                       N/A            Yes
  Inhibited cartilage degradation associated with neutrophil adhesion   Tobetto *et al.*, 1993 \[[@B92]\]         Rat peritoneal neutrophils exposed to bovine cartilage             Yes            Yes
  Suppressed neutrophil aggregation and adhesion                        Forrester ackie, 1981 \[[@B93]\]          Rabbit neutrophils; various HA doses and MWs                       Yes            Yes
  Stimulated PMN leukocyte phagocytosis, adherence, and migration       Håkansson *et al.*, 1980 \[[@B91]\]       Human PMN leukocytes from patients with impaired host resistance   N/A            N/A

HA, hyaluronan (hyaluronic acid); MW, molecular weight; OA, osteoarthritis; PMN, polymorphonuclear.

###### 

Effects of hyaluronan (hyaluronic acid) and hylans on cartilage

  Effect                                                                                                                                                                     Reference                                       Experimental model/treatment/endpoints                                                                                                                                                                   MW-dependent
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  Suppressed cartilage degeneration                                                                                                                                          Shimizu *et al.*, 1998 \[[@B18]\]               Rabbit ACL transection; HA (five weekly injections) or crosslinked HA (three weekly injections) 4 weeks PS; observations 9 weeks PS                                                                      Yes
                                                                                                                                                                             Listrat *et al.*, 1997 \[[@B10]\]               Clinical study of OA patient (*n*= 36; 1 year); three weekly HA injections every 3 months; arthroscopic evaluation 1 year from study start                                                               N/A
  Prevented cartilage damage                                                                                                                                                 Ghosh *et al.*, 1995 \[[@B53]\]                 Ovine meniscectomy; HA (five weekly injections) given 16 weeks PS; joint articular cartilage histologically graded 5 weeks after last injection                                                          N/A
  Prevented cartilage damage; maintained normal morphology                                                                                                                   Schiavinato *et al.*, 1989 \[[@B20]\]           Pond-Nuki canine OA model; HA given 1--7 weeks PS or 7--17 weeks PS; observations 7, 13, and 17 weeks PS                                                                                                 N/A
  Preserved cartilage histology and smoothness                                                                                                                               Yoshimi *et al.*, 1994 \[[@B102]\]              Rabbit ACL resection; HA (various MWs) injections one week PS weekly until assessments were made (6 or 12 weeks)                                                                                         Yes
                                                                                                                                                                             Sakakibara *et al.*, 1994 \[[@B103]\]           Rabbits immobilized at the onset of HA administration; HA (various MWs) twice/week for 5 weeks; observations 1--6 weeks after immobilization                                                             Yes
                                                                                                                                                                             Fu *et al.*, 2001 \[[@B94]\]                    Immobilization-induced cartilage degradation in rabbits; six weekly injections of HA with remobilization; assessments 1 week after the last injection                                                    Yes
  Improved superficial cartilage layer and synovial membrane morphology; reduced synovial thickness and inflammation                                                         Frizziero *et al.*, 1998 \[[@B104]\]            Clinical study of OA patients (*n*= 40); HA (five weekly injections); cartilage and synovial biopsies and arthroscopy performed at baseline and 6 months after first injection                           N/A
  Improved synovium structure and synoviocyte morphology; reduced inflammatory cells in the synovium                                                                         Pasquali Ronchetti *et al.*, 2001 \[[@B105]\]   Clinical study of patients with primary and secondary OA (*n*= 99); HA (five weekly injections) or MP (three weekly injections); synovial biopsies 2--3 weeks pretreatment and 6 months post-treatment   N/A
  Improved superficial cartilage compactness and thickness; increased chondrocyte density (HA better results than MP for most parameters); improved chondrocyte morphology   Guidolin *et al.*, 2001 \[[@B106]\]             Clinical study of OA patients (*n*= 24); HA (five weekly injections) or MP (three weekly injections); biopsies taken 6 months from treatment initiation                                                  N/A
  Prevented cartilage damage; maintained cartilage thickness, area, and smoothness                                                                                           Yoshioka *et al.*, 1997 \[[@B19]\]              Rabbit ACL transection; HA given 4 weeks PS; assessed femoral condyles 9 weeks after surgery                                                                                                             N/A
  Prevented cartilage damage; maintained cartilage thickness, area, smoothness, and surface uniformity                                                                       Shimizu *et al.*, 1998 \[[@B95]\]               Rabbit ACL transection; HA given 4 weeks PS; assessed femoral condyles 21 weeks after surgery                                                                                                            N/A
  Maintained cartilage smoothness; prevented deep fissures and cracks in the cartilage surface                                                                               Wenz *et al.*, 2000 \[[@B101]\]                 Severe and resect canine ACL (Pond-Nuki); HA (five weekly injections) given 3, 6, or 12 weeks PS; assessed patella and patella/knee 5 weeks after last injection                                         N/A
  Enhanced meniscal regeneration; inhibited cartilage deterioration                                                                                                          Kobayashi *et al.*, 2000 \[[@B96]\]             Rabbit partial meniscectomy; HA (five weekly injections) 1 week PS; assessed meniscus and tibial cartilage 6 months PS                                                                                   N/A
  Reduced disease severity                                                                                                                                                   Marshall *et al.*, 2000 \[[@B99]\]              Canine OA models; hylan G-F 20 (three weekly injections) given 2 months PS; assessed 6 months after treatment                                                                                            N/A
  Accelerated migration of synovial cells; enhanced migration of chondrocytes when coincubated with bFGF                                                                     Maniwa *et al.*, 2001 \[[@B107]\]               Rabbit synovial cells and chondrocytes incubated with HA, bFGF, HA + bFGF                                                                                                                                N/A

ACL, anterior cruciate ligament; bFGF, basic fibroblastic growth factor; HA, hyaluronan (hyaluronic acid); MP, methylprednisolone; MW, molecular weight; OA, osteoarthritis; PS, postsurgery.
